Headlines about Axsome Therapeutics (NASDAQ:AXSM) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Axsome Therapeutics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned headlines about the company an impact score of 48.7527711029835 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern’s rankings:
- Axsome Therapeutics Inc (AXSM) Expected to Post Earnings of -$0.32 Per Share (americanbankingnews.com)
- Complex Regional Pain Syndrome Treatment Market Forecast to 2023 | Top manufacturers-Axsome Therapeutics, Inc … (thetechnicalprogress.com)
- Axsome Therapeutics, Inc. (AXSM) stock ends Yesterday with change of 0.00% (nasdaqfortune.com)
- Understanding Analyst Rating: Axsome Therapeutics, Inc. (AXSM) (nasdaqplace.com)
- Return on Equity (ROE) Evaluation LendingClub Corporation (NYSE:LC), Axsome Therapeutics, Inc. (NASDAQ:AXSM … (stocksnewspoint.com)
Several equities research analysts recently issued reports on AXSM shares. HC Wainwright began coverage on shares of Axsome Therapeutics in a report on Thursday, June 7th. They issued a “buy” rating and a $10.00 target price on the stock. BTIG Research restated a “buy” rating and set a $16.00 price objective on shares of Axsome Therapeutics in a report on Sunday, April 29th. Zacks Investment Research upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 8th. Finally, ValuEngine raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.08.
Axsome Therapeutics traded down $0.05, reaching $3.40, on Thursday, MarketBeat Ratings reports. The stock had a trading volume of 28,400 shares, compared to its average volume of 293,447. Axsome Therapeutics has a 1-year low of $2.05 and a 1-year high of $6.45. The firm has a market cap of $86.05 million, a PE ratio of -2.74 and a beta of -0.31. The company has a quick ratio of 2.95, a current ratio of 2.95 and a debt-to-equity ratio of 0.47.
Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.09. research analysts expect that Axsome Therapeutics will post -1.08 EPS for the current fiscal year.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.